Quantification of visceral adipose tissue in polycystic ovary syndrome: dual-energy X-ray absorptiometry versus magnetic resonance imaging

Abstract

Background

Polycystic ovary syndrome (PCOS) is associated with frequent overweight and abdominal obesity. Quantifying visceral adipose tissue (VAT) in PCOS patients can be a tool to assess metabolic risk and monitor effects of treatment. The latest dual-energy X-ray absorptiometry (DXA) technology can measure VAT and subcutaneous adipose tissue (SAT) in a clinical setting.

Purpose

To compare DXA-measurements of VAT and SAT with the gold standard MRI in women with PCOS.

Material and Methods

A cross-sectional study of 67 overweight women with PCOS was performed. Measurements of VAT and SAT were performed by DXA in a 5-cm thick transverse slice at the L4/L5 level and by MRI in a 1-cm thick transverse slice at the L3 level.

Results

Mean (SD) DXA-VAT was 81 (34) cm³, DXA-SAT was 498 (118) cm³, MRI-VAT was 117 (48) cm³, and MRI-SAT was 408 (122) cm³. MRI and DXA measures of VAT (r = 0.82, P < 0.001) and SAT (r = 0.92, P < 0.001) correlated closely, and DXA-VAT was stronger correlated with MRI-VAT than BMI (r = 0.62, P < 0.001) and waist circumference (r = 0.60, P < 0.001). DXA-VAT coefficient of variance was 6.7% and inter correlation coefficient was 0.98. Bland–Altman analyses showed DXA to slightly underestimate VAT and SAT measurements compared with MRI.

Conclusion

DXA and MRI measurements of VAT and SAT correlated closely despite different size of region of interest, and DXA-VAT was superior to waist circumference and BMI in estimating MRI-VAT. DXA showed high reproducibility making it is suitable for repeated measurements in the same individual over time.

Keywords

Visceral adipose tissue PCOS DXA MRI

Get full access to this article

View all access options for this article.

References

Onat

Avci

Barlan

et al.

Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004; 28: 1018–1025.

Abate

Burns

Peshock

et al.

Estimation of adipose tissue mass by magnetic resonance imaging: validation against dissection in human cadavers. J Lipid Res 1994; 35: 1490–1496.

Balen

Conway

Kaltsas

et al.

Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995; 10: 2107–2111.

DeUgarte

Bartolucci

Azziz

. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83: 1454–1460.

Moran

Misso

Wild

et al.

Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347–363.

Zhao

Zhu

Lou

et al.

Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget 2016; 7: 33715–33721.

Lim

Davies

Norman

et al.

Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2012; 18: 618–637.

Dolfing

Stassen

van Haard

PMM

et al.

Comparison of MRI-assessed body fat content between lean women with polycystic ovary syndrome (PCOS) and matched controls: less visceral fat with PCOS. Hum Reprod 2011; 26: 1495–1500.

Barber

Golding

Alvey

et al.

I. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 999–1004.

10.

Daan

NMP

Louwers

Koster

MPH

et al.

Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?

Fertil Steril 2014; 102: 1444–1451.

11.

Gast

den Heijer

Smit

JWA

et al.

NEO study group. Individual contributions of visceral fat and total body fat to subclinical atherosclerosis: The NEO study. Atherosclerosis 2015; 241: 547–554.

12.

Britton

Massaro

Murabito

et al.

Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol 2013; 62: 921–925.

13.

Bredella

Gill

Keating

et al.

Assessment of abdominal fat compartments using DXA in premenopausal women from anorexia nervosa to morbid obesity. Obesity 2013; 21: 2458–2464.

14.

Neeland

Grundy

et al.

Comparison of visceral fat mass measurement by dual-X-ray absorptiometry and magnetic resonance imaging in a multiethnic cohort: the Dallas Heart Study. Nutr Diabetes 2016; 6: e221–e221.

15.

Frøssing

Nylander

Kistorp

et al.

The LIPT-Study: on risk markers of vascular thrombosis in polycystic ovary syndrome. a randomized, double-blind, placebo-controlled study of the effect of liraglutide. J Obes Weight Loss Ther 2015; 5: 254–254.

16.

Maislin

Ahmed

Gooneratne

et al.

Single slice vs. volumetric MR assessment of visceral adipose tissue: reliability and validity among the overweight and obese. Obesity 2012; 20: 2124–2132.

17.

Abate

Garg

Coleman

et al.

Prediction of total subcutaneous abdominal, intraperitoneal, and retroperitoneal adipose tissue masses in men by a single axial magnetic resonance imaging slice. Am J Clin Nutr 1997; 65: 403–408.

18.

Bland

Altman

. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307–310.

19.

Stöckl

Dewitte

Thienpont

. Validity of linear regression in method comparison studies: is it limited by the statistical model or the quality of the analytical input data? Clin Chem 1998; 44: 2340–2346.

20.

Micklesfield

Goedecke

Punyanitya

et al.

Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat. Obesity 2012; 20: 1109–1114.

21.

Kaul

Rothney

Peters

et al.

Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity 2012; 20: 1313–1318.

22.

Katzmarzyk

Greenway

Heymsfield

et al.

Clinical utility and reproducibility of visceral adipose tissue measurements derived from dual-energy X-ray absorptiometry in White and African American adults. Obesity 2013; 21: 2221–2224.

23.

Sam

. Adiposity and metabolic dysfunction in polycystic ovary syndrome. Horm Mol Biol Clin Investig 2015; 21: 107–116.

24.

Gooren

LJG

Giltay

. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med 2008; 5: 765–776.

25.

Kuchenbecker

WKH

Groen

van Asselt

et al.

In women with polycystic ovary syndrome and obesity, loss of intra-abdominal fat is associated with resumption of ovulation. Hum Reprod 2011; 26: 2505–2512.